Literature DB >> 3678449

Leishmania major: the suitability of East African nonhuman primates as animal models for cutaneous leishmaniasis.

J I Githure1, G D Reid, A A Binhazim, C O Anjili, A M Shatry, L D Hendricks.   

Abstract

The susceptibility of four species of East African nonhuman primates to experimental infection with Leishmania major was investigated. Four Syke's monkeys (Cercopithecus mitis), two vervet monkeys (Cercopithecus aethiops), two baboons (Papio cynocephalus), and two brown bushbabies (Galago garnettii) were each inoculated intradermally on the left eyelid, left ear, and nose with 0.1 ml of medium containing 1 x 10(7) promastigotes of a characterized L. major strain. All the nonhuman primates except the bushbabies developed erythema and conspicuous nodules on the eyelids and ears by 3 weeks PI. The nodules increased rapidly in size and ulceration was evident on the eyelids and ears by 49 days PI in the vervets, Syke's, and baboons. The aspirates were positive in culture or smears at 35, 49, 63, and 77 days PI. No parasites were observed in cultures or smears at 92, 105, 128, 147, and 161 days PI. The lesions in these animals began resolving by 84 days PI and were completely healed by 112 days PI. The exception was one baboon in which lesion healing did not start until around 147 days and was completely healed by 182 days PI. Cultures from the liver failed to demonstrate visceralization of the parasite in any of the animals throughout the 68 weeks of the experiment. Challenge with the same strain of L. major 6 months PI, corresponding to about 3 months after self cure, failed to produce infection in any of these experimental hosts. All the nonhuman primates except the bushbaby when challenged with the same strain of L. major at 12 months PI developed lesions and were positive for parasites at 14 and 28 days PI. Positive cultures were obtained from the eyelid and ear of one vervet up to 42 days PI. However, the lesion sizes in all these animals were smaller than in the initial infection and did not ulcerate. The nodules disappeared within 6 to 8 weeks as compared to 16 weeks in the initial infection. The histopathological appearance of the lesions varied from diffuse infiltration of plasma cells and lymphocytes which increased progressively to granulomata with epitheloid cells. This study shows that the vervets, Syke's, and the baboons are equally susceptible to L. major infection, while bushbabies are refractory. The vervets, Syke's, and baboons demonstrate a self-healing phenomenon within about 3 months which is comparable to that observed in humans infected with L. major. These three species of nonhuman primates are therefore considered as suitable models for drug or vaccine trials against human zoonotic cutaneous leishmaniasis.

Entities:  

Mesh:

Year:  1987        PMID: 3678449     DOI: 10.1016/0014-4894(87)90058-0

Source DB:  PubMed          Journal:  Exp Parasitol        ISSN: 0014-4894            Impact factor:   2.011


  7 in total

1.  Vervet monkeys vaccinated with killed Leishmania major parasites and interleukin-12 develop a type 1 immune response but are not protected against challenge infection.

Authors:  M M Gicheru; J O Olobo; C O Anjili; A S Orago; F Modabber; P Scott
Journal:  Infect Immun       Date:  2001-01       Impact factor: 3.441

2.  Protection against cutaneous leishmaniasis induced by recombinant antigens in murine and nonhuman primate models of the human disease.

Authors:  A Campos-Neto; R Porrozzi; K Greeson; R N Coler; J R Webb; Y A Seiky; S G Reed; G Grimaldi
Journal:  Infect Immun       Date:  2001-06       Impact factor: 3.441

3.  Cell-mediated responses of immunized vervet monkeys to defined Leishmania T-cell epitopes.

Authors:  A J Curry; A Jardim; J O Olobo; R W Olafson
Journal:  Infect Immun       Date:  1994-05       Impact factor: 3.441

4.  Immunity to visceral leishmaniasis using genetically defined live-attenuated parasites.

Authors:  Angamuthu Selvapandiyan; Ranadhir Dey; Sreenivas Gannavaram; Ines Lakhal-Naouar; Robert Duncan; Poonam Salotra; Hira L Nakhasi
Journal:  J Trop Med       Date:  2011-09-06

Review 5.  Route map for the discovery and pre-clinical development of new drugs and treatments for cutaneous leishmaniasis.

Authors:  Diana Caridha; Brian Vesely; Katrien van Bocxlaer; Byron Arana; Charles E Mowbray; Sima Rafati; Silvia Uliana; Rosa Reguera; Mara Kreishman-Deitrick; Richard Sciotti; Pierre Buffet; Simon L Croft
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2019-06-20       Impact factor: 4.077

6.  Non-human primates and Leishmania immunity.

Authors:  Sonia André; Vasco Rodrigues; Morgane Picard; Ricardo Silvestre; Jérôme Estaquier
Journal:  Cytokine X       Date:  2020-10-12

Review 7.  A Review: The Current In Vivo Models for the Discovery and Utility of New Anti-leishmanial Drugs Targeting Cutaneous Leishmaniasis.

Authors:  Emily Rose Mears; Farrokh Modabber; Robert Don; George E Johnson
Journal:  PLoS Negl Trop Dis       Date:  2015-09-03
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.